Health news
Intermittent dosing of zolpidem with placebo after one month of full dose nightly zolpidem is an effective acute and extended treatment for patients with chronic insomnia while using 50% less medication, according to study results…
The Food and Drug Administration has approved Solaris Pharma’s Abbreviated New Drug Application for clindamycin phosphate EQ 1% topical gel, the first generic version of Clindagel® (Bausch Health). Clindamycin phosphate EQ 1% gel is indicated…
What does Modern Slavery look like? 11 days ago, on the Daily Blog, I introduced Michael and Simone Glen, long-time Caltex franchisees in Christchurch. I wrote about their vicious bullying campaign to break and drive…
Every month, the leadership team at the Gerontological Advanced Practice Nurses Association (GAPNA) highlights the most important published literature that impacts geriatric practice. This month, Valerie K. Sabol, PhD, MBA, ACNP, GNP, ANEF, FAANP, FAAN,…
Full results from the phase 3 EMPEROR-Preserved trial showed that treatment with empagliflozin demonstrated significant risk reduction of cardiovascular death or hospitalization for heart failure in adults with heart failure and preserved ejection fraction. The…
Roche is voluntarily withdrawing the indication for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, paclitaxel bound to albumin [human]; nab-paclitaxel) in the United States (US) for the treatment of adults with unresectable locally advanced or…
The Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for bamlanivimab plus etesevimab to state that the combination should only be administered in states, territories, and US jurisdictions in which the…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021